Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Argus Health
Boehringer Ingelheim
Federal Trade Commission
Medtronic
Citi
Moodys
AstraZeneca
McKesson

Generated: January 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Sereno, Inc. v. Ferring (D. Mass. 2002)

« Back to Dashboard

Sereno, Inc. v. Ferring (D. Mass. 2002)

Docket ➤ Try a Free Trial Date Filed 2002-09-18
Court District Court, D. Massachusetts Date Terminated 2005-01-07
Cause 35:271 Patent Infringement Assigned To Mark Lawrence Wolf
Jury Demand Defendant Referred To
Parties PHARMACEUTICALS FERRING; SERENO, INC.
Patents 4,589,402; 4,845,077
Attorneys Brian P. Akers; Daniel A. Boehnen; Elizabeth Brenner; Erin D.E. Joffre; Fred A. Kelly , Jr.; Grantland G. Drutchas; John J. McDonnell; Kristin Dulong Kuperstein; Michael T. Gass; Nicole A. Keenan; Reed M. Staheli; Ronald M. Wawrzyn; Stephen A. Bent
Firms Foley & Lardner; McDonnell Boehnen Hulbert & Berghoff LLP; Nixon Peabody, LLP; Seventh Floor; U.S. International Trade Commission
Link to Docket External link to docket
Small Molecule Drugs cited in Sereno, Inc. v. Ferring
The small molecule drugs covered by the patents cited in this case are ➤ Try a Free Trial , ➤ Try a Free Trial , ➤ Try a Free Trial , and ➤ Try a Free Trial .

Details for Sereno, Inc. v. Ferring (D. Mass. 2002)

Date Filed Document No. Description Snippet Link To Document
2004-05-26 131 United States Patent No. 4,589,402 ("the '402 patent") and United States Patent No. 4,845,…4,845,077 ("the '077 patent"). This hearing was conducted at an early stage in the case, prior… exogeneous LH" in Claim 1 of the '402 patent and "FSH ... in the absence of exogeneous…exogeneous LH" in Claims 1 and 8 of the '077 patent are, as agreed by the parties, construed to have…gonadotropin treatment" in Claim 13 of the '077 patent is construed to mean: "a method of limiting External link to document
2003-12-22 83 least claims 1 and 3 of U.S. Pat. No. 4,589,402 (“the `402 patent”) (Exhibit 1) and at least claims 1, …Claimed In The Patents In Suit ....................................... 8 1 . The `402 patent ...........… is given ” ( `402 patent, claim 3) 17 D. Additional Limitations in the `077 Patent ..................…. No. 4,845,077 (“the `077 patent”) (Exhibit 2). The `402 and `077 patents reflect important discoveries…exogenous LH” (`402 patent, claim l); o “gonadotropin releasing hormone antagonist” (`077 patent, claim 1 and External link to document
2003-12-22 84 the ‘402 patent”) Exhibit 2 U.S. Pat. No. 4,845,077 (“the ‘077 patent”) Exhibit 3 ‘402 Patent File History…October 15, 1985 (Amendment A) Exhibit 4 ‘07"7 Patent File History, Amendment Under Rule 115 dated Oct…Steril. No. 4, 629-34 (April 1984) Exhibit 8 ‘077 Patent File History, Response to Final Rejection dated…dated May 28, 1985 (Amendment B) Exhibit 9 ‘077 Patent File History, Arnendment Under Rule 115 dated Nov…Nov. 18, 1988 (Amendment H) Exhibit 10 ‘077 Patent File History, Form 1449 Exhibit 11 Kumar v. 'Ovonic External link to document
2003-12-19 85 Serono patents. Serono’s patents are U.S. Patent Nos. 4,845,077 (the “‘077” patent) and 4,589,402 (the …402” patent). The ‘077 patent dates to an application filed on April 3, 1984, and the ‘402 patent dates… her patent and communicated, first to the patent examiner and ultimately to the public. Patents should…July 26, 1984. Neither patent contains product claims. They are both method patents. Ferring competes with…in this case. Certainly ‘077 patent claims 1, 2, 8, and 9 and ‘402 patent claims 1 and 3 are at issue. External link to document
2003-12-19 86 Exhibit B is a true and correct copy of U.S. Patent No. 4,589,402 titled “Method of In Vitro Fertilization…as Exhibit A is a true and correct copy of U.S. Patent No. 4,845,077 titled “Method of Inducing Ovulation… true and correct copy of Paper 7 from the ‘077 Patent Prosecution History titled “Response to Final …true and correct copy of` Paper 6 from the ‘077 Patent Prosecution History titled “Examiner’s Action” …true and correct copy of Paper 14 from the ‘077 Patent Prosecution History titled “Examiner Interview External link to document
2004-01-14 90 invention claimed in both U.S. patents No. 4,845,077 (“‘077”) and No. 4,589,402 (“‘402”) is indisputably the…the ‘402 patent (Brief, pp. 7, 13-16). Of course, Metrodin is not mentioned in either patent', nor…inventor set forth in his or her patent and communicated, first to the patent examiner and ultimately to the…frame of 1984, which is the filing year for both patents in suit. Serono concedes that the infertility-…, Response to Final Rejection. In contrast, the patent claims underscore the one-hormone therapy, by using External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Argus Health
Merck
Federal Trade Commission
Chinese Patent Office
QuintilesIMS
AstraZeneca
Fish and Richardson
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.